Authors
Shaheer Koniyan, Mohammad A Khan, Manisha Ahir, Anil G Jegga, Maureen D Mayes, David Gius, Justin Leung, Mark D Bonnen, Sydney B Montesi, Prasanna Krishnamurthy, Yohannes T Ghebre
Published in
The Journal of pharmacy and pharmacology. Volume 78. Issue 11. Nov 04, 2026.
Abstract
To investigate whether esomeprazole attenuates profibrotic responses in dermal fibroblasts from patients with systemic sclerosis (SSc), as well as inflammatory and oxidative stress-related responses in dermal endothelial cells, and to evaluate its effects on nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway.
To evaluate this, primary dermal fibroblasts from patients with limited SSc were stimulated with transforming growth factor-beta 1 (TGF-β1) to induce profibrotic processes and then treated with esomeprazole. Functional studies showed that esomeprazole reversed aberrant fibroblast contractility, and RNA sequencing (RNA-seq) analysis demonstrated that esomeprazole upregulated antioxidant gene networks and downregulated profibrotic pathways. Intriguingly, the upregulation of HO-1 by esomeprazole was blunted upon genetic deletion of the Nrf2 gene. Microvascular injury is an early event in scleroderma and a precursor of fibrosis. As such, we treated microvascular endothelial cells with the prooxidant molecule bleomycin, with and without esomeprazole, and found that esomeprazole attenuated the expression of pro-inflammatory cytokines.
Together, these results suggest that esomeprazole upregulates the Nrf2/HO-1 pathway and attenuates profibrotic responses in SSc dermal fibroblasts and reduces inflammatory and oxidative stress-related responses in dermal endothelial cells, supporting further evaluation of the drug in preclinical scleroderma models.
PMID:
43043866
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0